+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tyverb"

From
Tyverb - API Insight, 2022 - Product Thumbnail Image

Tyverb - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Tyverb- Drug Insight, 2019 - Product Thumbnail Image

Tyverb- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

The Tyverb market is a subset of the larger lung cancer drug market. It is composed of drugs that are used to treat non-small cell lung cancer (NSCLC). These drugs are used to target specific mutations in the epidermal growth factor receptor (EGFR) gene, which is found in many NSCLC tumors. Tyverb drugs are designed to block the activity of the mutated EGFR gene, thus preventing the tumor from growing and spreading. The Tyverb market is a rapidly growing segment of the lung cancer drug market, with new drugs being developed and approved for use. These drugs are typically used in combination with other treatments, such as chemotherapy and radiation, to provide the best possible outcome for patients. Some of the companies in the Tyverb market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more